Malaria drug Chloroquine helps fight treatment resistant brain cancer

After her brain cancer became resistant to chemotherapy and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. Now a paper published in the journal eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased both the quantity and quality of her life: Adding the… Continue reading Malaria drug Chloroquine helps fight treatment resistant brain cancer

Alcohol intake and Melanoma risk

Researchers at Warren Alpert Medical School of Brown University in Providence, Rhode Island found that alcohol intake was associated with higher rates of invasive melanoma among white men and women. White wine carried the most significant association, and the increased risk was greater for parts of the body that receive less sun exposure. The findings… Continue reading Alcohol intake and Melanoma risk

Protein CPEB4 plays crucial role in melanoma

Spanish National Cancer Research Centre (CNIO) Melanoma Group researchers work tirelessly to identify biomarkers of tumor progression and to validate novel therapeutic targets in melanoma. In particular, their research focuses on discovering features that define the “fingerprint” of this tumor, features that distinguish it from other cancer types. The latest study in this area, published… Continue reading Protein CPEB4 plays crucial role in melanoma

Virtual clinical trials use mathematical modelling to predict melanoma response

Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling. A study led by Alexander “Sandy” Anderson, Ph.D., chair of IMO, and Eunjung Kim, Ph.D., an applied research scientist, shows how mathematical modeling can accurately predict patient responses… Continue reading Virtual clinical trials use mathematical modelling to predict melanoma response

Synthetic binding protein called "NS1 Monobody" found to inhibit common cancer causing (RAS) mutation

Monobody NS1 binds to H-RAS or K-RAS protein and blocksRAS function by disrupting the protein’s ability to form active molecular pairs. Credit: John P. O’Bryan, et al.  Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers. Mutations in… Continue reading Synthetic binding protein called "NS1 Monobody" found to inhibit common cancer causing (RAS) mutation

Synthetic binding protein called “NS1 Monobody” found to inhibit common cancer causing (RAS) mutation

Monobody NS1 binds to H-RAS or K-RAS protein and blocksRAS function by disrupting the protein’s ability to form active molecular pairs. Credit: John P. O’Bryan, et al.  Researchers at the University of Illinois at Chicago have identified a new way to block the action of genetic mutations found in nearly 30 percent of all cancers. Mutations in… Continue reading Synthetic binding protein called “NS1 Monobody” found to inhibit common cancer causing (RAS) mutation